Comparative Pharmacology
Head-to-head clinical analysis: ERY TAB versus ERYMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERY TAB versus ERYMAX.
ERY-TAB vs ERYMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
None Documented
None Documented
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic